ACET
ACET
Positions held
Your positionsACET isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | — | Enterprise value | — | Trailing P/E | — | Forward P/E | — |
| PEG | — | Price / book | — | Beta | — | Dividend yield | — |
| Revenue growth | — | Earnings growth | — | Gross margin | — | Operating margin | — |
| Profit margin | — | ROE | — | ROA | — | Debt / equity | — |
| Current ratio | — | Free cash flow | — | Analyst recommendation | — | Mean target | — |
| 52w high | — | 52w low | — |
Quarterly
No data yet.
Yearly (6y)
No data yet.
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-03 · Adicet Bio’s Prula-Cel Delivers 54% Lupus Remission Rate at 12 Months
2026-09-30 · Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
2026-09-28 · Adicet Bio Reports Positive Prula-cel Phase 1 Lupus Data as Pivotal Study Plans Advance
2026-09-28 · Is Tenet Healthcare (THC) Outperforming Other Medical Stocks This Year?
2026-09-28 · Adicet Bio Reports Phase 1 Prula-cel Data in Lupus Patients
2026-09-03 · Wall Street Analysts See a 258.21% Upside in Adicet Bio (ACET): Can the Stock Really Move This High?
2026-09-03 · Is Adicet Bio (ACET) Outperforming Other Medical Stocks This Year?
2026-09-02 · Adicet Bio to Participate in Fireside Chat at H.C. Wainwright 28th Annual Global Investment Conference
2026-08-31 · Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
Price (daily)
Full chart · RSI · MACD · patterns